The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

Publisher: Blackwell Publishing

E-ISSN: 1097-0142|120|24|3853-3858

ISSN: 0008-543X

Source: Cancer, Vol.120, Iss.24, 2014-12, pp. : 3853-3858

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract